| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8683644 | Epilepsy & Behavior | 2018 | 4 Pages |
Abstract
Antiglutamate decarboxylase (anti-GAD) antibodies relate to epilepsy with or without cognitive complaints. However, psychiatric symptoms were almost absent in anti-GAD positive patients, and the presence of anti-GAD antibodies contributed little to the prognosis in our cohort.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Anita M. Vinke, Frédéric L.W.V.J. Schaper, Mariëlle C.G. Vlooswijk, Joost Nicolai, Marian H.J.M. Majoie, Pilar Martinez Martinez, Carolin Hoffmann, Jan G.M.C. Damoiseaux, Rob P.W. Rouhl,